American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma
(2021) In Transplantation and cellular therapy 27(9). p.720-728- Abstract
Autologous (auto-) and allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities in contemporary treatment algorithms for mantle cell lymphoma (MCL). Chimeric antigen receptor (CAR) T cell therapy recently received approval for MCL; however, its exact place and sequence in relation to HCT remain unclear. The American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and the European Society for Blood and Marrow Transplantation jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-HCT, allo-HCT, and CAR T cell therapy for patients with newly diagnosed and relapsed/refractory (R/R)... (More)
Autologous (auto-) and allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities in contemporary treatment algorithms for mantle cell lymphoma (MCL). Chimeric antigen receptor (CAR) T cell therapy recently received approval for MCL; however, its exact place and sequence in relation to HCT remain unclear. The American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and the European Society for Blood and Marrow Transplantation jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-HCT, allo-HCT, and CAR T cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated, with a few key statements as follows: in the first line setting, auto-HCT consolidation represents standard of care in eligible patients, whereas there is no clear role of allo-HCT or CAR T cell therapy outside of clinical trials. In the R/R setting, the preferential option is CAR T cell therapy, especially in patients with MCL failing or intolerant to at least one Bruton's tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T cell therapy fails or is infeasible. Several recommendations were based on expert opinion, where the panel developed consensus statements for important real-world clinical scenarios to guide clinical practice. In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MCL.
(Less)
- author
- organization
- publishing date
- 2021-09-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Allogeneic transplantation, Autologous transplantation, CAR T cell, Cellular therapy, Consensus, Mantle cell lymphoma
- in
- Transplantation and cellular therapy
- volume
- 27
- issue
- 9
- pages
- 9 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:34452722
- scopus:85115347371
- ISSN
- 2666-6367
- DOI
- 10.1016/j.jtct.2021.03.001
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: Copyright © 2021. Published by Elsevier Inc. All rights reserved.
- id
- f9508008-e3f6-4ec4-818e-0058e7d50c69
- date added to LUP
- 2021-10-14 14:47:02
- date last changed
- 2024-04-06 10:43:35
@article{f9508008-e3f6-4ec4-818e-0058e7d50c69,
abstract = {{<p>Autologous (auto-) and allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities in contemporary treatment algorithms for mantle cell lymphoma (MCL). Chimeric antigen receptor (CAR) T cell therapy recently received approval for MCL; however, its exact place and sequence in relation to HCT remain unclear. The American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and the European Society for Blood and Marrow Transplantation jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-HCT, allo-HCT, and CAR T cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated, with a few key statements as follows: in the first line setting, auto-HCT consolidation represents standard of care in eligible patients, whereas there is no clear role of allo-HCT or CAR T cell therapy outside of clinical trials. In the R/R setting, the preferential option is CAR T cell therapy, especially in patients with MCL failing or intolerant to at least one Bruton's tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T cell therapy fails or is infeasible. Several recommendations were based on expert opinion, where the panel developed consensus statements for important real-world clinical scenarios to guide clinical practice. In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MCL.</p>}},
author = {{Munshi, Pashna N. and Hamadani, Mehdi and Kumar, Ambuj and Dreger, Peter and Friedberg, Jonathan W. and Dreyling, Martin and Kahl, Brad and Jerkeman, Mats and Kharfan-Dabaja, Mohamed A. and Locke, Frederick L. and Shadman, Mazyar and Hill, Brian T. and Ahmed, Sairah and Herrera, Alex F. and Sauter, Craig S. and Bachanova, Veronika and Ghosh, Nilanjan and Lunning, Matthew and Kenkre, Vaishalee P. and Aljurf, Mahmoud and Wang, Michael and Maddocks, Kami J. and Leonard, John P. and Kamdar, Manali and Phillips, Tycel and Cashen, Amanda F. and Inwards, David J. and Sureda, Anna and Cohen, Jonathon B. and Smith, Sonali M. and Carlo-Stella, Carmello and Savani, Bipin and Robinson, Stephen P. and Fenske, Timothy S.}},
issn = {{2666-6367}},
keywords = {{Allogeneic transplantation; Autologous transplantation; CAR T cell; Cellular therapy; Consensus; Mantle cell lymphoma}},
language = {{eng}},
month = {{09}},
number = {{9}},
pages = {{720--728}},
publisher = {{Elsevier}},
series = {{Transplantation and cellular therapy}},
title = {{American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma}},
url = {{http://dx.doi.org/10.1016/j.jtct.2021.03.001}},
doi = {{10.1016/j.jtct.2021.03.001}},
volume = {{27}},
year = {{2021}},
}